Why is THG stock surging today?

THG shares rose 13.7% to 31.3p after the group raised full-year adjusted EBITDA guidance to £103m, above the prior £101.7m consensus, and confirmed its first positive free-cash-flow year since its IPO. Last-twelve-month adjusted EBITDA increased 50% year-on-year to £100.6m; THG Nutrition revenue grew 5.3% in Q3, while whey protein prices were down approximately 20% since September’s interim results. Management said it expects revenue growth to accelerate in Q4; the FTSE 250 fell around 0.6%, so the article attributes THG’s gain to company-specific news.

Analysis

The key question is whether the earnings-quality improvement is durable, not whether the guidance increment justifies today’s repricing. The reported beat over consensus is narrow; the much larger share-price response appears to price a lower probability of renewed cash burn and a successful Q4. Verify that free cash flow reflects repeatable operating cash conversion rather than working-capital timing, and that adjusted EBITDA reconciles to cash after capex and other adjustments.

Lower whey costs should support Nutrition margins only if savings flow through before selling prices or promotions reset. Wider retail and foodservice distribution can expand reach, but may dilute direct-to-consumer economics or increase dependence on channel partners. Competitors such as Bulk and Applied Nutrition could intensify promotions, limiting pass-through. The UK rates backdrop is an additional valuation headwind for a recovery story whose payoff depends on sustained future cash generation.

Near term, momentum may persist into Q4, but chasing a one-day surge leaves asymmetric event risk. Over 1–3 months, the decisive evidence is Q4 revenue quality, gross-margin progression and cash conversion. Over 6–18 months, continued growth with positive cash generation would support a more credible rerating; reversal in whey costs, heavier discounting or weak cash conversion would undermine it. The contrarian risk is that investors are treating a small guidance beat and one favorable input-cost move as proof of a structural turnaround.

Key Decisions for Investors

• Do not chase the initial gap higher. Consider a starter long only on a pullback or after confirmation that Q4 trading sustains revenue growth and cash conversion; keep exposure modest because the recovery thesis remains execution-dependent.
• Use the next results and trading updates to check reported cash from operations against adjusted EBITDA, working-capital movements, capex and reconciliation items. Treat positive free cash flow as a watch item until its components show repeatability.
• Track whey prices alongside Nutrition gross margin and promotional intensity. If input savings accrue without a material rise in discounts, the margin thesis strengthens; if margins fail to improve despite cheaper whey, reassess the long.
• Falsify the recovery thesis if Q4 revenue momentum stalls, full-year guidance is cut, or cash generation reverses. A renewed increase in whey costs or UK rate expectations would also weaken the risk/reward.